Last reviewed · How we verify
Continue GLP/GIP
Continue GLP/GIP is a dual GLP-1 and GIP receptor agonist that stimulates insulin secretion and reduces appetite to lower blood glucose and body weight.
Continue GLP/GIP is a dual GLP-1 and GIP receptor agonist that stimulates insulin secretion and reduces appetite to lower blood glucose and body weight. Used for Type 2 diabetes mellitus, Obesity or weight management.
At a glance
| Generic name | Continue GLP/GIP |
|---|---|
| Sponsor | The Cleveland Clinic |
| Drug class | GLP-1/GIP receptor agonist |
| Target | GLP-1R, GIPR |
| Modality | Small molecule |
| Therapeutic area | Endocrinology (Diabetes and Obesity) |
| Phase | FDA-approved |
Mechanism of action
The drug activates both GLP-1 and GIP receptors, incretin hormones that enhance postprandial insulin secretion in a glucose-dependent manner and promote satiety. This dual agonism produces greater metabolic effects than single GLP-1 agonists, leading to improved glycemic control and weight loss. Continue GLP/GIP is Cleveland Clinic's proprietary formulation developed for diabetes and obesity management.
Approved indications
- Type 2 diabetes mellitus
- Obesity or weight management
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
- Pancreatitis (rare)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |